A Phase 2 interventional study of Heated lidocaine/tetracaine patch in Myofascial Pain Syndromes, sponsored by ZARS Pharma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-16.
Sponsored by ZARS Pharma Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Myofascial Pain Syndromes with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Myofascial Pain Syndromes · United States.
Among the 36 studies in Myofascial Pain Syndromes with a site in United States, this one is the 22nd largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2010, is one of 6 in phase 2, and was the 5th registered.
339 studies on the registry are indexed under Myofascial Pain Syndromes; 66 are open to participants now.
Browse Myofascial Pain Syndromes studies →8 of the 36 studies in Myofascial Pain Syndromes with a site in United States are open now. Recruiting first, the newest first:
University of California, Davis · Sites in United States
Ages 18+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–65 · Healthy volunteers
University of Arizona · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Myofascial Pain Syndromes studies recruiting now, 5 (15%) set no upper age limit and 26 (76%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 50 across 307 interventional studies indexed under Myofascial Pain Syndromes.
Median enrollment 50 across the 31 interventional studies, 90 across the 5 observational. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 36 have an industry lead sponsor. The 10 most frequent:
ZARS Pharma Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
ZARS Pharma Inc. has 1 study filed under Myofascial Pain Syndromes — fewer than ten, so there is no comparison to draw.
3 of the studies in Myofascial Pain Syndromes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04732507University of ArizonaInvestigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome | 2026-12-09 |
| NCT07832422Nova Southeastern UniversityIschemic Compression and Low-Level Laser Therapy for Myofascial Low Back Pain | 2027-03 |
| NCT07278570Mayo ClinicMagnetic Resonance Elastography to Monitor Response to Manual Therapy in Myofascial Pain | 2027-08-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Myofascial Pain Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this pilot study is to explore the potential usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with myofascial trigger points.
The purpose of this pilot study is to explore the usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with myofascial trigger points. The study will consist of a 2-week, open-label treatment period followed by a 2 week follow-up period conducted at a single study site. Eligible patients must have a clinical diagnosis of pain (minimum 1-month duration) associated with up to 3 identifiable myofascial trigger points. A number of efficacy variables will be employed to evaluate their utility for assessing painful responses in this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Active
Drug: Heated lidocaine/tetracaine patch
Drug page: Lidocaine
Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch directly to each trigger point identified at the Screening/Baseline Visit (up to 3 trigger points). Patches will be administered for 4 hours, 2 times per day (total of 8 hours for each trigger point per day).
Also known as: Synera
Pain intensity
Time frame: Two weeks
Pain interference with activities (eg, general, normal work, sleep)
Time frame: Two weeks
The record gives a start of Jun 2010, a primary completion of Dec 2010 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidocaine